Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
Medtronic
Mallinckrodt
Express Scripts

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

DOXY-LEMMON Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Doxy-lemmon, and when can generic versions of Doxy-lemmon launch?

Doxy-lemmon is a drug marketed by Teva and is included in two NDAs.

The generic ingredient in DOXY-LEMMON is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

US ANDA Litigation and Generic Entry Outlook for Doxy-lemmon

A generic version of DOXY-LEMMON was launched as doxycycline hyclate by CARIBE HOLDINGS on December 14th, 2019.

Summary for DOXY-LEMMON
Drug patent expirations by year for DOXY-LEMMON
Synonyms for DOXY-LEMMON
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; ethanol; hydrate; dihydrochloride
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; ethanol; hydrate; dihydrochloride
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; ethanol; hydrate; dihydrochloride
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide - ethanol (2:1) dihydrochloride hydrate
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide compound with ethanol (2:1) dihydrochloride hydrate
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;ethanol;hydrate;dihydrochloride
10592-13-9
10592-13-9 (. HCl)
19XTS3T51U
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride, (4S,4aR,5S,5aR,6R,12aS)-, compd. with ethanol, hydrate (2:2:1:1)
2-Naphthacenecarboxamide, 4beta-(dimeethylamino)-1,4,4abeta,5,5abeta,6,11,12a-octahydro-3,5beta,10,12,12abeta-pentahydroxy-6beta-methyl-1,11-dioxo-, monohydrochloride, compd. with ethyl alcohol (2:1), monohydrate
2387AH
24390-14-5
2C22H24N2O8.C2H6O.2ClH.H2O
2C22H24N2O8.C2H6O.H2O
4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate
6-Deoxy-5-hydroxytetracycline hydrochloride hemihydrate
62149-53-5
AC-6017
AC1NQZPV
AC1NUYS5
Acticlate
Acticlate CAP
AK175707
AKOS025402170
AN-18097
Atridox
bis((4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide) ethanol hydrate dihydrochloride
CHEMBL3989740
D02129
Dentista
Doryx
Doryx (TN)
Doryx Mpc
Doxteric
DOXY
Doxy 100
DOXY 200
Doxychel Hyclate
Doxycycline hyclate
Doxycycline Hyclate (100 mg)
Doxycycline hyclate (internal use)
Doxycycline hyclate (USP)
Doxycycline hyclate [USAN:USP]
doxycycline hyclate 20 mg twice daily
Doxycycline hydrochloride hemiethanolate hemihydrate
Doxycycline hydrochloride hydrate (JP17)
DOXYCYCLINE HYLATE
Doxyprex
DS-9077
DTXSID4041020
Ethanol, compd. with (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride (1:2), monohydrate
Hydramycin
LS-174052
MFCD07357237
MolPort-005-932-536
Monodoks
Periostat
Periostat (TN)
Roximycin
SW219440-1
SW219440-2
Tetraclean
UNII-19XTS3T51U
Vibra-tabs (TN)
Vibramycin hyclate
Vivox
WC 2031
Z2791720087

US Patents and Regulatory Information for DOXY-LEMMON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva DOXY-LEMMON doxycycline hyclate CAPSULE;ORAL 062497-001 Aug 23, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
Teva DOXY-LEMMON doxycycline hyclate CAPSULE;ORAL 062497-002 Jun 15, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
Teva DOXY-LEMMON doxycycline hyclate TABLET;ORAL 062581-001 Mar 15, 1985 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
AstraZeneca
Colorcon
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.